Do you want to read an article? Please log in or register.
Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial
COPD
Related content
RECOMMENDED
COPD
Influence of heart failure (HF) comorbidity in chronic obstructive pulmonary disease (COPD) and isolated forms of HF and COPD on cardiovascular function during hospitalization
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Med
Schafauser NS, Sampaio LMM, Heubel AD, Kabbach EZ, Kawakami DMO, Leonardi NT, Castello-Simões V, Borghi-Silva A, Mendes RG
doi: 10.1016/j.rmed.2024.107731
COMMENTED
COPD
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended and commented by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Dakin P, Maloney J, Lu X, Bauer D, Bansal A, Abdulai RM, Robinson LB
doi: 10.1016/S2213-2600(24)00409-0
COPDEmphysema
Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS)
Respir Med
Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Dakin P, Maloney J, Lu X, Bauer D, Bansal A, Robinson LB, Abdulai RM
doi: 10.1016/j.rmed.2024.107846
RECOMMENDED
COPDFurther Publications
Global, regional, and national burden of chronic obstructive pulmonary disease and its attributable risk factors from 1990 to 2021: an analysis for the Global Burden of Disease Study 2021
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Respir Res
Wang Z, Lin J, Liang L, Huang F, Yao X, Peng K, Gao Y, Zheng J
doi: 10.1186/s12931-024-03051-2
COMMENTED
COPD
Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine Reduces Exacerbation Rate and Risk in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
★ 3
Recommended and commented by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Chest
Sciurba FC, Christenson SA, Rheault T, Bengtsson T, Rickard K, Barjaktarevic IZ
doi: 10.1016/j.chest.2024.07.168
RECOMMENDED
COPDInterstitial Lung Disease
Pulmonary Rehabilitation and Functional Independence: Impact on Survival in Patients with Fibrotic Interstitial Lung Disease or Chronic Obstructive Pulmonary Disease
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Med
Elmiger A, Marcin T, Bovet L, Brun P, Guler SA
doi: 10.1016/j.rmed.2024.107933
RECOMMENDED
COPD
Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Singh D, Brightling CE, Rabe KF, Han MK, Christenson SA, Drummond MB, Papi A, Pavord ID, Molfino NA, Almqvist G, Kotalik A, Hellqvist Å, Gołąbek M, Sindhwani NS, Ponnarambil SS, COURSE study investigators
doi: 10.1016/S2213-2600(24)00324-2
RECOMMENDED
COPD
The responsiveness of different exercise tests in Chronic Obstructive Pulmonary Disease: a randomised controlled trial
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Chest
Harvey-Dunstan TC, Baldwin MM, Tal-Singer R, Allinder M, Polkey MI, Hamilton A, Richardson M, Edwards SA, Steiner MC, Morgan MD, Singh SJ, COPD/MAP Consortium
doi: 10.1016/j.chest.2024.05.051
RECOMMENDED
COPD
Use of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitor is Associated with reduced Emergency Room Visits and Hospitalization in Patients with Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Diabetes Mellitus
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Med
Shanmugavel Geetha H, Teo YX, Ravichandran S, Perkitt NR, Gogtay M, Lal A, Abraham GM, Trivedi N
doi: 10.1016/j.rmed.2024.107819